EMAIL THIS PAGE TO A FRIEND

Clinical cancer research : an official journal of the American Association for Cancer Research

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.


PMID 25649019

Abstract

To investigate the clinical relevance of PTEN in HER2-amplified and HER2-nonamplified disease. We assessed PTEN status in two large adjuvant breast cancer trials (BCIRG-006 and BCIRG-005) using a PTEN immunohistochemical (IHC) assay that was previously validated in a panel of 33 breast cancer cell lines and prostate cancer tissues with known PTEN gene deletion. In the HER2-positive patient population, absence of tumor cell PTEN staining occurred at a rate of 5.4% and was independent of ER/PR status. In contrast, 15.9% of HER2-negative patients exhibited absence of PTEN staining with the highest frequency seen in triple-negative breast cancer (TNBC) subgroup versus ER/PR-positive patients (35.1% vs. 10.9%). Complete absence of PTEN staining in tumor cells was associated with poor clinical outcome in HER2-positive disease. Those patients whose cancers demonstrated absent PTEN staining had a significant decrease in disease-free survival (DFS) and overall survival (OS) compared with patients with tumors exhibiting any PTEN staining patterns (low, moderate, or high). Trastuzumab appeared to provide clinical benefit even for patients lacking PTEN staining. In the HER2-negative population, there were no statistically significant differences in clinical outcome based on PTEN status. This study is the largest to date examining PTEN status in breast cancer and the data suggest that the rate and significance of PTEN status differ between HER2-positive and HER2-negative disease. Furthermore, the data clearly suggest that HER2-positive patients with PTEN loss still benefit from trastuzumab.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4300337
Anti-PTEN (Ab-370) antibody produced in rabbit, affinity isolated antibody
SAB4300336
Anti-PTEN (Ab-380/382/383) antibody produced in rabbit, affinity isolated antibody
SAB2501614 Anti-PTEN antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1406331
Anti-PTEN antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
P7482
Anti-PTEN antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB3500337
Anti-PTEN antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB4502473
Anti-PTEN, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4502474
Anti-PTEN, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4502475
Anti-PTEN, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4502476
Anti-PTEN, C-Terminal antibody produced in rabbit, affinity isolated antibody
WH0005728M1
Monoclonal Anti-PTEN antibody produced in mouse, clone 2G9, purified immunoglobulin, buffered aqueous solution
P3487
Monoclonal Anti-PTEN antibody produced in mouse, ~1 mg/mL, purified immunoglobulin, clone PTN-18, buffered aqueous solution
SAB1404272
Monoclonal Anti-PTEN antibody produced in mouse, clone 3E7, purified immunoglobulin, buffered aqueous solution
SAB4100580
Monoclonal Anti-PTEN antibody produced in mouse, clone PTEN-A552, culture supernatant
PLA0133
Rabbit anti-PTEN Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.